EZH2 and metabolic dysfunction-associated steatotic liver disease: However, we suggest that opposite effect of EZH2 expression and EZH2 inhibitor might cause NASH model difference between HFa/HFr-D induced NAFLD and streptozotocin (STZ)/high-fat induced NASH model.